Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients

9/24 Late treatment study

Shoaibi et al., medRxiv, doi:10.1101/2020.09.23.20199463 (Preprint)
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients

Source PDF Share Tweet

Retrospective database analysis focused on Famotidine but also showing results for HCQ users, with unadjusted mortality RR 0.85, p<0.001 (13.6% vs. 16.1%).

Shoaibi et al., 9/24/2020, retrospective, database analysis, USA, North America, preprint, 5 authors.

risk of death, 15.4% lower, RR 0.85, p < 0.001, treatment 686 of 5047 (13.6%), control 3923 of 24404 (16.1%).

This study is excluded in meta analysis: unadjusted results with no group details.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 344 studies Meta Analysis

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit